$HCM: Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with …

Date: Friday, August 23rd, 2019

Stock(s) mentioned:

Source: Benzinga (https://www.benzinga.com)

Summary: LONDON, Aug. 23, 2019 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (NASDAQ:HCM) has initiated a Phase I study of HMPL-523, …

Full article address: https://www.benzinga.com/pressreleases/19/08/g14317535/chi-med-initiates-a-phase-i-trial-of-hmpl-523-in-patients-with-immune-thrombocytopenia-itp-in-chin

Related News:

$HCM: Chi-Med announces updated data on cancer candidates

$HCM: Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

$HCM: Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in …

$HCM: Chi-Med begins early-stage HMPL-523 trial in patients with ITP in …

$HCM: Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 …

$HCM: Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call …

$HCM: Chi-Med Reports 2019 Interim Results and Provides Updates on …

$HCM: Week In Review: Jibeier Pharma Files To Raise $100 Million In IPO …

$HCM: Why Chi-Med Stock Is Tanking Today

$CDMO $AXLA $HCM: Avid Bioservices and ImmunoGen among healthcare gainers …

$HCM: Chi-Med prices upsized ADS offering; shares down 11% premarket

Latest News:

$SQ: Investors Should Still Consider Square Stock

$BWAY: BrainsWay Announces Further Leadership Transition to US

$COHR: Is Coherent a Buy?

$BA: Airbus Hikes Forecast For Future Freighter Demand

$DAN: Dana Announces Recipients of 2018 Supplier Awards

$BFAM: Bright Horizons Named One of the 2019 Best Workplaces for …

$EURN $GNK $GOGL: Ocean Rate Report: Saudi Attacks Spark Higher Tanker Earnings

$UBER $FB: 3 Ways To Gain Exposure To Venture Capital In Tech And Healthcare

$OSTK: Patrick Byrne Sells All of His Overstock Shares Following Crypto …

$DRI $CLWT: Mid-Morning Market Update: Markets Open Higher; Darden …

$T $DISH: AT&T Stock Is Doomed to Become the Next GE